Academic sponsorship

Time to treat as independent

BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c6837 (Published 30 November 2010)
Cite this as: BMJ 2010;341:c6837

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Tom MacDonald, professor of clinical pharmacology1,
  2. Chris Hawkey, professor of gastroenterology2,
  3. Ian Ford, professor of biostatistics3
  1. 1Medicines Monitoring Unit, Division of Medical Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
  2. 2University Hospital Nottingham, Wolfson Digestive Diseases Centre, Nottingham NG7 2UH, UK
  3. 3Robertson Centre for Biostatistics, University of Glasgow, Glasgow G12 8QQ, UK
  1. tom{at}memo.dundee.ac.uk

In response to the rosiglitazone affair, Steinbrook and Kassirer suggest that more trials should be sponsored, funded, and conducted by organisations independent of industry.1 We agree. We operate close to that model with two studies requested by the European Medicines Agency. Academics wrote the protocols, collaborators are academic, and the study data …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL